Allianz Asset Management Gmb H Glycomimetics Inc Transaction History

Allianz Asset Management Gmb H

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$2.8 - $12.85 $559,722 - $2.57 Million	-199,901 Closed	0 $0
Q2 2019 Aug 08, 2019	SELL	$10.6 - $13.12 $288,076 - $356,562	-27,177 Reduced 11.97%	199,901 $2.38 Million
Q1 2019 May 13, 2019	BUY	$9.96 - $13.44 $1.12 Million - $1.52 Million	112,871 Added 98.83%	227,078 $2.83 Million
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $35,921 - $62,385	-4,241 Reduced 3.58%	114,207 $1.08 Million
Q3 2018 Nov 13, 2018	BUY	$13.7 - $17.12 $1.47 Million - $1.84 Million	107,384 Added 970.57%	118,448 $1.71 Million
Q2 2018 Aug 13, 2018	SELL	$14.63 - $19.19 $912,458 - $1.2 Million	-62,369 Reduced 84.93%	11,064 $178,000
Q1 2018 May 14, 2018	BUY	$16.06 - $25.35 $1.18 Million - $1.86 Million	73,433 New	73,433 $1.19 Million

17.6M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.